ReviewWorld journal of critical care medicine2019
Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.
Review in World journal of critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Challenges in Maintaining the Hemostatic Balance in Children Undergoing Extracorporeal Membrane Oxygenation: A Systematic Literature Review.Frontiers in pediatrics · 2020Pooled it
- Prolonged Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation in Sheep.Annals of biomedical engineering · 2026Article
- Evaluation of bivalirudin-based anticoagulation for extracorporeal membrane oxygenation, including patients with COVID-19.The journal of extra-corporeal technology · 2026Article
- Concurrent use of continuous kidney replacement therapy during extracorporeal membrane oxygenation: what pediatric nephrologists need to know-PCRRT-ICONIC practice points.Pediatric nephrology (Berlin, Germany) · 2025Review
- ECMO for bridging lung transplantation.European journal of medical research · 2024Review
- Improving ECMO therapy: Monitoring oxygenator functionality and identifying key indicators, factors, and considerations for changeout.The journal of extra-corporeal technology · 2024Review
- Evaluation of Bivalirudin During Adult Extracorporeal Membrane Oxygenation: A Retrospective Characterization of Dosing, Efficacy and Bleeding.Hospital pharmacy · 2024Article
- A Comprehensive Review of Extra Corporeal Membrane Oxygenation: The Lifeline in Critical Moments.Cureus · 2024Review
- Anticoagulants in adult extracorporeal membrane oxygenation: alternatives to standardized anticoagulation with unfractionated heparin.European journal of clinical pharmacology · 2023Review
- Extracorporeal Membrane Oxygenation in Acute Respiratory Failure.Pulmonary therapy · 2023Review
- Anticoagulation Management during Extracorporeal Membrane Oxygenation-A Mini-Review.Medicina (Kaunas, Lithuania) · 2022Review
- Thrombus formation during ECMO: Insights from a detailed histological analysis of thrombus composition.Journal of thrombosis and haemostasis : JTH · 2022Article
- Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.The journal of extra-corporeal technology · 2022Article
- Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review.Journal of clinical medicine · 2022Review
- Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors.Journal of cardiothoracic and vascular anesthesia · 2022Observational
- Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.Materials today. Bio · 2022Review
- Successful Application of Argatroban During VV-ECMO in a Pregnant Patient Complicated With ARDS due to Severe Tuberculosis: A Case Report and Literature Review.Frontiers in pharmacology · 2022Article
- The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Article
- Quantitative prediction model for affinity of drug-target interactions based on molecular vibrations and overall system of ligand-receptor.BMC bioinformatics · 2021Article
- New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices.Membranes · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing. Systemic anticoagulation is an essential element in the care of extracorporeal membrane oxygenation patients. While unfractionated heparin is the most commonly used agent, unfractionated heparin is associated with several unique complications that can be catastrophic in critically ill patients, including heparin-induced thrombocytopenia and acquired antithrombin deficiency. These complications can result in thrombotic events and subtherapeutic anticoagulation. Direct thrombin inhibitors (DTIs) are emerging as alternative anticoagulants in patients supported by extracorporeal membrane oxygenation. Increasing evidence supports DTIs use as safe and effective in extracorporeal membrane oxygenation patients with and without heparin-induced thrombocytopenia. This review outlines the pharmacology, dosing strategies and available protocols, monitoring parameters, and special use considerations for all available DTIs in extracorporeal membrane oxygenation patients. The advantages and disadvantages of DTIs in extracorporeal membrane oxygenation relative to unfractionated heparin will be described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.